Development of molecular diagnosis and molecule-targeted therapy for leukemia
| Project/Area Number |
17015028
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
SUGIYAMA Haruo Osaka University, 大学院・医学系研究科, 教授 (70162906)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKA Yoshihiro 大阪大学, 大学院・医学系研究科, 講師 (20273691)
OJI Yusuke 大阪大学, 大学院・医学系研究科, 特任教授 (20294100)
HOSEN Naoki 大阪大学, 大学院・医学系研究科, 准教授 (10456923)
FUJIKI Fumihiro 大阪大学, 大学院・医学系研究科, 特任助教(常勤) (40456926)
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥129,500,000 (Direct Cost: ¥129,500,000)
Fiscal Year 2009: ¥24,300,000 (Direct Cost: ¥24,300,000)
Fiscal Year 2008: ¥24,300,000 (Direct Cost: ¥24,300,000)
Fiscal Year 2007: ¥27,100,000 (Direct Cost: ¥27,100,000)
Fiscal Year 2006: ¥27,100,000 (Direct Cost: ¥27,100,000)
Fiscal Year 2005: ¥26,700,000 (Direct Cost: ¥26,700,000)
|
|---|
| Keywords | WT1 / 白血病 / 分子診断 / 分子標的療法 / 免疫療法 / 分子標的治療 / 分子標的治療法 / 免役療法 / 遺伝子 / 癌 / 免疫学 |
|---|
| Research Abstract |
Wilms' tumor gene WT1 is overexpressed in leukemia and almost all types of solid tumors. Therefore, WT1 is a pan-tumor marker and pan-tumor-associated antigen. WT1 mRNA quantitative assay, which can detect minimal residual disease of luekamia at high sensitivity, has been developed and covered by national health insurance from 2007. Furthermore, clinical trials of WT1 peptide-based immunotherapy was begun in 2001 and clinical effect has been showing. This immunotherapy has been developing in Europe and USA and drug product is in progress.
|
Report
(6 results)
Research Products
(59 results)
-
[Journal Article] Prognostic Significance of WT1 mRNA and anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.2010
Author(s)
Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva O. A, Oka Y, Oji Y, Sugiyama H, Ogata K.
-
Journal Title
Leukemia Research (in press)
Related Report
Peer Reviewed
-
[Journal Article] High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow (BM) in tumor-bearing patients: an important role of BM as a secondary lymphoid organ.2010
Author(s)
Murao A, Oka Y, Tsuboi A, Elisseeva OA, Harada Y, Fujiki F, Nakajima H, Nishida S, Hosen N, Shirakata T, Hashimoto N, Myoui A, Ueda T, Takeda Y, Osaki T, Enomoto T, Yoshikawa H, Kimura T, Oji Y, Kawase I, Sugiyama H.
-
Journal Title
Cancer Science (in press)
Related Report
Peer Reviewed
-
[Journal Article] Biased usage of BV gene families of T cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies2010
Author(s)
Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva O, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H.
-
Journal Title
Cancer Science 101
Pages: 594-600
NAID
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] A WT1 protein-derived, naturally processed 16-mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells.2008
Author(s)
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama H.
-
Journal Title
Microbiol Immunol 52
Pages: 591-600
Related Report
Peer Reviewed
-
[Journal Article] Identification of a WT1 protein-derived peptide, WT1187 as an HLA-A*0206-restricted, WT1-specific CTL epitope" is currently at the following stage of production.2008
Author(s)
Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H.
-
Journal Title
Microbiol Immunol 52
Pages: 551-8
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] Identification and characterization of a WT1 (Wilms' tumor gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.2007
Author(s)
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Oji Y, Sugiyama H.
-
Journal Title
J Immunother 30
Pages: 282-93
Related Report
Peer Reviewed
-
[Journal Article] Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 mug/body) in a patient with chronic myelomonocytic leukemia.2007
Author(s)
Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y, Tsukaguchi M, Shirakata T, Nishida S, Nakajima H, Morita S, Sakamoto J, Kawase I, Oji Y, Sugiyama H.
-
Journal Title
Int J Hematol 85
Pages: 426-9
Related Report
Peer Reviewed
-
-
-
[Journal Article] A phase I/II trial of a WT1 (Wilms' Tumor Gene) peptide vaccine in patients with solid malignancy: Safety assessment based on the phase I data.2006
Author(s)
Morita S, Oka Y., Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J.
-
Journal Title
Japanese Journal of Clinical Oncology 36
Pages: 231-236
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.2005
Author(s)
Wu F, Oka Y, Tsuboi A, Elisseeva O. A, Nakajima H, Fujiki F, Masuda T, Murakami M, Yoshihara S, Ikegame K, Hosen N, Kawakami M, Nakagawa M, Kubota T, Soma T, Yamagami T, Tsukaguchi M, Ogawa H, Oji Y, Hamaoka T, Kawase I, Sugiyama H.
-
Journal Title
Leukemia 19
Pages: 268-274
Related Report
Peer Reviewed
-
[Journal Article] Generation of human tumor-specific, HLA class I-restricted Th1 and Tc1 cells by cell engineering with tumor peptide-specific T cell receptor genes.2005
Author(s)
Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T.
-
Journal Title
Related Report
Peer Reviewed
-
[Journal Article] WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.2005
Author(s)
Li Z, Oka Y, Tsuboi A, Masuda T, Tatsumi N, Kawakami M, Fujioka T, Sakaguchi N, Nakajima H, Fujiki F, Udaka K, Oji Y, Kawase I, Sugiyama H.
-
Journal Title
Int J Hematol 82
Pages: 458-459
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] WT1 peptide vaccination at very low-dose for myelodysplastic syndrome.2007
Author(s)
Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y, Hayashi T, Nishida S, Shirakata T; Hosen N, Nakajima H, Yamagami T, Soma T, Oji Y, Sugiyama H.
Organizer
3rd International Conference on WT1 in Human Malignancies
Place of Presentation
Berlin
Year and Date
2007-09-19
Related Report
-
-
-
-
-
-
[Presentation] WT1 specific CTLs in WT1 peptide vaccine-treated patients2005
Author(s)
Olga Elisseeva, Yoshihiro Oka, Akihiro Tsuboi, Hiroshi Hase, Hiroko Nakajima, Yukie Harada, Manabu Kawakami, Fumihiro Fujiki, Sumiyuki Nishida, Toshiaki Shirakata, Satoshi Oono, Ichirou Kawase, Yusuke Oji, Haruo Sugiyama
Organizer
The Second International Conference on WT1 in Human Neoplasia
Place of Presentation
Kyoto
Year and Date
2005-10-22
Related Report
-
[Presentation] WT1-peptide vaccination for acute myeloid leukemia2005
Author(s)
Manabu Kawakami, Yoshihiro Oka, Akihiro Tsuboi, Hiroko Nakajima, Olga A. Elisseeva, Hiroshi Hase, Yukie Harada, Fumihiro Fujiki, Zheyu LI, Tatsumi, Sumiyuki Nishida, Satoshi Ohno, Toshiaki Shirakata, Ichiro Kawase, Yusuke Oji, Haruo Sugiyama
Organizer
The Second International Conference on WT1 in Human Neoplasia
Place of Presentation
Kyoto
Year and Date
2005-10-22
Related Report
-
[Presentation] Identification and characterization of a WT1 (Wilms' tumor gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes2005
Author(s)
Fumihiro Fujiki, Yoshihiro Oka, Akihiro Tsuboi, Manabu Kawakami, Mai Kawakatsu, Hiroko Nakajima, Olga A. Elisseeva, Yukie Harada, Ken Ito, Zheyu Li, Naoya Tatsumi, Nao Sakaguchi, Tatsuya Fujioka, Tomoki Masuda, Masaki Yasukawa, Keiko Udaka, Yusuke Oji, Haruo Sugiyama
Organizer
The Second International Conference on WT1 in Human Neoplasia
Place of Presentation
Kyoto
Year and Date
2005-10-21
Related Report
-
-
-
[Presentation] WT1特異的CD4*ヘルパーT細胞を誘導できるHLA-classII拘束性ペプチドの同定2005
Author(s)
藤木文博, 岡芳弘, 坪井昭博, 川上学, 川勝真衣, 中島博子, オリガ・エリセーバ, 原田ゆきえ, 李哲雨, 伊藤憲, 宇高恵子, 尾路祐介, 杉山治夫
Organizer
第64回日本癌学会学術総会
Place of Presentation
札幌
Year and Date
2005-09-16
Related Report
-
-
-
[Presentation] 骨髄異形成症候群(MDS)に対する少量WT1ペプチド療法2005
Author(s)
川上学, 坪井昭博、原田ゆきえ, 中島博子, 白方俊章, 大野智, 藤木文博, 李哲雨, エリセーバ・オリガ, 尾路祐介, 古川佳央, 岡芳弘, 杉山治夫
Organizer
第9回基盤的癌免疫研究会総会
Place of Presentation
東京
Year and Date
2005-07-15
Related Report
-
-
-
-
-
-
-
